Seegene expands European footprint with new France subsidiary
Seegene, Inc. announced the establishment of a new subsidiary in France to reinforce its European presence and support global sales expansion.
The new subsidiary will strengthen local engagement with customers and partners through enhanced technical support, market development and collaboration with healthcare stakeholders.
According to global market research firm Grand View Research, Inc., France’s MDx market is estimated to reach approximately EUR 600 million, accounting for around 15 percent of Europe’s total. It is the second-largest market in the region after Germany, which holds a 19 percent share. Demand in France is particularly high for diagnostic tests targeting sexually transmitted infections (STIs), gastrointestinal (GI) tract infections, and respiratory infections. Through its subsidiary, Seegene aims to expand sales of these product lines while introducing a broader portfolio including cervical cancer and other multiplex diagnostic categories.
The subsidiary also provides a strategic foothold for the European rollout of Seegene’s solutions that are in development, CURECA, a fully automated, unmanned PCR system, and STAgora, a real-time diagnostic data analytics and predictive insights platform.
The addition of France brings Seegene’s overseas sales subsidiaries to eight, complementing its global distribution network of 90 distributors across 94 countries.
As of the first half of 2025, overseas sales accounted for approximately 93 percent of Seegene’s total revenue, with Europe representing 63 percent. The region remains a key growth driver for the company’s global expansion roadmap.
